S&P 500   3,273.49 (-0.08%)
DOW   28,734.21 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.74 (+2.73%)
MSFT   168.21 (+1.66%)
GOOGL   1,458.91 (+0.58%)
AMZN   1,859.86 (+0.36%)
CGC   23.49 (-1.80%)
MU   55.43 (-1.84%)
GE   12.95 (+10.31%)
TSLA   580.01 (+2.31%)
ACB   1.92 (-2.53%)
F   8.86 (-1.23%)
PRI   120.11 (-0.44%)
BAC   32.99 (-0.75%)
DIS   136.16 (-1.60%)
GILD   64.25 (-0.17%)
S&P 500   3,273.49 (-0.08%)
DOW   28,734.21 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.74 (+2.73%)
MSFT   168.21 (+1.66%)
GOOGL   1,458.91 (+0.58%)
AMZN   1,859.86 (+0.36%)
CGC   23.49 (-1.80%)
MU   55.43 (-1.84%)
GE   12.95 (+10.31%)
TSLA   580.01 (+2.31%)
ACB   1.92 (-2.53%)
F   8.86 (-1.23%)
PRI   120.11 (-0.44%)
BAC   32.99 (-0.75%)
DIS   136.16 (-1.60%)
GILD   64.25 (-0.17%)
S&P 500   3,273.49 (-0.08%)
DOW   28,734.21 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.74 (+2.73%)
MSFT   168.21 (+1.66%)
GOOGL   1,458.91 (+0.58%)
AMZN   1,859.86 (+0.36%)
CGC   23.49 (-1.80%)
MU   55.43 (-1.84%)
GE   12.95 (+10.31%)
TSLA   580.01 (+2.31%)
ACB   1.92 (-2.53%)
F   8.86 (-1.23%)
PRI   120.11 (-0.44%)
BAC   32.99 (-0.75%)
DIS   136.16 (-1.60%)
GILD   64.25 (-0.17%)
S&P 500   3,273.49 (-0.08%)
DOW   28,734.21 (+0.04%)
QQQ   221.81 (+0.16%)
AAPL   324.32 (+2.09%)
FB   223.74 (+2.73%)
MSFT   168.21 (+1.66%)
GOOGL   1,458.91 (+0.58%)
AMZN   1,859.86 (+0.36%)
CGC   23.49 (-1.80%)
MU   55.43 (-1.84%)
GE   12.95 (+10.31%)
TSLA   580.01 (+2.31%)
ACB   1.92 (-2.53%)
F   8.86 (-1.23%)
PRI   120.11 (-0.44%)
BAC   32.99 (-0.75%)
DIS   136.16 (-1.60%)
GILD   64.25 (-0.17%)
Log in

VERONA PHARMA P/S News Headlines (NASDAQ:VRNA)

$5.75
-0.13 (-2.21 %)
(As of 01/29/2020 04:00 PM ET)
Today's Range
$5.70
Now: $5.75
$6.10
50-Day Range
$3.99
MA: $5.44
$7.23
52-Week Range
$3.65
Now: $5.75
$12.89
Volume60,406 shs
Average Volume394,576 shs
Market Capitalization$75.73 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.78

Headlines

VERONA PHARMA P/S (NASDAQ VRNA) News Headlines

Source:
DateHeadline
VERONA PHARMA P/S (NASDAQ:VRNA) Short Interest UpdateVERONA PHARMA P/S (NASDAQ:VRNA) Short Interest Update
www.americanbankingnews.com - January 26 at 6:58 PM
Verona Pharma: Not Enough Cash To Demonstrate The Clinical Benefit For Its Key Drug CandidateVerona Pharma: Not Enough Cash To Demonstrate The Clinical Benefit For Its Key Drug Candidate
seekingalpha.com - January 23 at 4:01 PM
VERONA PHARMA P/S (NASDAQ:VRNA) Expected to Announce Earnings of -$1.12 Per ShareVERONA PHARMA P/S (NASDAQ:VRNA) Expected to Announce Earnings of -$1.12 Per Share
www.americanbankingnews.com - January 20 at 2:22 AM
Head-To-Head Review: Jaguar Health (NASDAQ:JAGX) versus VERONA PHARMA P/S (NASDAQ:VRNA)Head-To-Head Review: Jaguar Health (NASDAQ:JAGX) versus VERONA PHARMA P/S (NASDAQ:VRNA)
www.americanbankingnews.com - January 18 at 5:56 AM
VERONA PHARMA P/S Expected to Post FY2020 Earnings of ($3.02) Per Share (NASDAQ:VRNA)VERONA PHARMA P/S Expected to Post FY2020 Earnings of ($3.02) Per Share (NASDAQ:VRNA)
www.americanbankingnews.com - January 17 at 10:45 AM
VERONA PHARMA P/S (NASDAQ:VRNA) to Post FY2024 Earnings of $0.89 Per Share, Wedbush ForecastsVERONA PHARMA P/S (NASDAQ:VRNA) to Post FY2024 Earnings of $0.89 Per Share, Wedbush Forecasts
www.americanbankingnews.com - January 15 at 8:06 AM
VERONA PHARMA P/S (NASDAQ:VRNA) Price Target Raised to $34.00 at SunTrust BanksVERONA PHARMA P/S (NASDAQ:VRNA) Price Target Raised to $34.00 at SunTrust Banks
www.americanbankingnews.com - January 14 at 9:23 AM
Verona Pharma up 59% premarket on positive ensifentrine dataVerona Pharma up 59% premarket on positive ensifentrine data
seekingalpha.com - January 13 at 5:37 PM
VERONA PHARMA P/S (NASDAQ:VRNA) PT Raised to $60.00 at WedbushVERONA PHARMA P/S (NASDAQ:VRNA) PT Raised to $60.00 at Wedbush
www.americanbankingnews.com - January 13 at 4:57 PM
Verona Pharma Says Ensifentrine Study Shows Positive ResultsVerona Pharma Says Ensifentrine Study Shows Positive Results
www.lse.co.uk - January 13 at 3:46 AM
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium TherapyVerona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
www.benzinga.com - January 13 at 3:46 AM
VERONA PHARMA P/S (NASDAQ:VRNA) Sees Significant Increase in Short InterestVERONA PHARMA P/S (NASDAQ:VRNA) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 11 at 1:58 AM
Big Day Awaits Verona Pharma (VRNA) On MondayBig Day Awaits Verona Pharma (VRNA) On Monday
www.nasdaq.com - January 10 at 9:16 PM
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New YorkVerona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
finance.yahoo.com - November 11 at 8:30 AM
Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q3 2019 Results - Earnings Call TranscriptVerona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 9:13 AM
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
finance.yahoo.com - September 30 at 3:52 PM
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment ConferenceVerona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
finance.yahoo.com - September 3 at 10:51 AM
Verona Pharma plc: PDMR DealingVerona Pharma plc: PDMR Dealing
finance.yahoo.com - August 9 at 9:12 AM
Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019Verona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
finance.yahoo.com - August 6 at 9:41 AM
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPDVerona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
finance.yahoo.com - August 5 at 9:39 AM
Verona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development UpdateVerona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
finance.yahoo.com - July 30 at 9:31 AM
Verona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare ConferenceVerona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 24 at 10:15 AM
Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPDVerona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
finance.yahoo.com - June 4 at 9:52 AM
Verona Pharma to Present at Jefferies 2019 Global Healthcare ConferenceVerona Pharma to Present at Jefferies 2019 Global Healthcare Conference
finance.yahoo.com - May 30 at 9:49 AM
Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International ConferenceVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
finance.yahoo.com - May 20 at 1:13 PM
Verona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 TrialsVerona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
www.globenewswire.com - May 7 at 9:42 AM
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK BrokerVerona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
www.nasdaq.com - May 1 at 9:35 AM
Verona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK BrokerVerona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
finance.yahoo.com - May 1 at 9:35 AM
Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
finance.yahoo.com - April 25 at 9:46 AM
Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate EnsifentrineVerona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine
finance.yahoo.com - April 9 at 10:21 AM
Verona Pharma to Present at H.C. Wainwright Global Life Sciences ConferenceVerona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 26 at 9:56 AM
Dr. Martin Edwards Joins Verona Pharma as Non-Executive DirectorDr. Martin Edwards Joins Verona Pharma as Non-Executive Director
finance.yahoo.com - March 21 at 8:05 AM
Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development UpdateVerona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
finance.yahoo.com - February 26 at 10:18 AM
Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - February 1 at 9:59 AM
Verona Pharma Enters Oversold TerritoryVerona Pharma Enters Oversold Territory
finance.yahoo.com - January 16 at 9:39 AM
Verona Pharmas nebulized ensifentrine shows mixed results in pharmacology studyVerona Pharma's nebulized ensifentrine shows mixed results in pharmacology study
seekingalpha.com - January 14 at 9:15 AM
Verona Pharma Sees Hammer Chart Pattern: Time to Buy?Verona Pharma Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - January 11 at 10:08 AM
Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554Verona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
finance.yahoo.com - January 9 at 9:52 AM
Verona Pharma PLC American Depositary Share (VRNA)Verona Pharma PLC American Depositary Share (VRNA)
www.zacks.com - January 4 at 4:47 PM
Verona Pharma PLC ADRVerona Pharma PLC ADR
www.barrons.com - December 18 at 4:34 PM
Verona Pharma plc (VRNA) Commences Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDVerona Pharma plc (VRNA) Commences Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
www.streetinsider.com - December 17 at 9:42 AM
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPDVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
finance.yahoo.com - December 17 at 9:42 AM
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel